SS&C (SSNC) Q2 2026 earnings review
Growth Accelerates, Margin Expands, Buybacks Surge
SS&C delivered a stellar Q2 2026, driven by a sharp acceleration in adjusted organic revenue growth to 7.6% (up from 5.0% in Q1). The quarter was characterized by a powerful rebound in economically sensitive segments like Intralinks and Wealth & Investment Tech, complementing the steady performance of its core fund administration businesses. Management capitalized on the strong $716M year-to-date operating cash flow by aggressively returning capital, executing a record $435M in share repurchases. While guidance was raised for the full year, Q3 organic growth guidance implies a deceleration back to the 5.0% range.
🐂 Bull Case
The 7.6% organic growth beat expectations, driven by Intralinks (+7.4%) and Wealth (+9.8%) bouncing back aggressively, showing the company's diversified model captures upside when macro conditions improve.
EBITDA margins hit 39.5% (+50 bps YoY), generating massive cash flow that funded an aggressive 6.4 million share repurchase, making EPS growth highly accretive.
🐻 Bear Case
Despite heavy marketing around AI and 'Customer Zero' strategies, the Intelligent Automation & Analytics segment (Blue Prism) organic growth reversed into negative territory (-1.0%).
The Healthcare segment remains a persistent laggard, dropping 3.1% organically this quarter, proving management's previous claims of 'lumpiness' might be masking structural headwinds.
⚖️ Verdict: 🟢
Bullish. The top-line acceleration is undeniable, and the willingness to deploy 100% of allocated capital toward buybacks ($435M) signals extreme management confidence. The core business is firing on all cylinders.
Key Themes
Intralinks and Wealth Segments Reversing to Growth
After a sluggish start to the year, both Intralinks and Wealth and Investment Technologies shifted from macro-driven headwinds to powerful tailwinds. Intralinks growth accelerated from 3.2% in Q1 to 7.4% in Q2, reflecting a pickup in global M&A deal volumes. More impressively, the Wealth segment reversed from a 0.4% contraction in Q1 to a 9.8% surge in Q2. This proves SS&C's diversified model works: when core administration is steady, these transactional segments provide explosive upside.
Fund Administration Core Remains Accelerating
The foundational engines of the company—GlobeOp and GIDS—continue to post exceptional numbers. GlobeOp accelerated to 9.0% organic growth (up from 6.7% in Q1), while GIDS posted a robust 8.9%. Combined, these segments represent roughly $3.37B of the company's annualized revenue base, proving the 'lift-out' and alternative asset growth strategies are highly durable.
Aggressive Capital Returns Accelerating
Management backed up its bullish Q1 rhetoric by drastically accelerating buybacks. SS&C repurchased a record 6.4 million shares for $435.2 million in Q2, compared to just $168 million in Q1. Returning 100% of allocated capital directly to shareholders while maintaining a 2.75x net leverage ratio highlights excellent cash generation and a commitment to EPS accretion.
AI Narrative Contradicted by Segment Data
A major concern emerged regarding the Intelligent Automation & Analytics segment (which houses Blue Prism and AI initiatives). Despite management's heavy promotion of 'Blue Prism WorkHQ' and AI agent monetization in prior quarters, the segment's organic growth reversed into negative territory (-1.0% in Q2 vs +0.5% in Q1). If AI is a massive tailwind, it is not yet translating to the top line of the dedicated automation unit.
Healthcare Segment Remains a Drag
The Healthcare segment reversed its Q1 gain (+3.7%) to drop 3.1% organically in Q2. Management previously blamed this on the 'lumpiness' of large license deals and contract timing, but persistent underperformance raises questions about SS&C's competitive positioning in this specific vertical compared to its dominance in financial services.
Other KPIs
Stable and expanding. The margin increased 50 bps year-over-year from 39.0% in Q2 2025, keeping the company perfectly on track toward management's previously stated goal of reaching a 40% margin by Q4 2026. This expansion reflects successful cost controls and internal efficiency measures.
Stable. The consolidated net leverage ratio sits comfortably at 2.75x, practically unchanged from Q1's 2.76x. This stability, achieved despite spending $435M on buybacks, demonstrates the sheer cash-generating power of the business model.
Guidance
Decelerating. The midpoint of $1,677 million implies 5.0% organic growth. While solid, this represents a deceleration from the explosive 7.6% organic growth achieved in the current Q2, suggesting management might be conservatively modeling the sustainability of the Intralinks and Wealth segment surges.
Accelerating slightly. The company raised the midpoint of its full-year guidance from $6,744 million to $6,752 million. This brings the implied full-year organic growth midpoint to 5.5% (up from 5.3% previously guided), completely validating the strong Q2 performance.
Accelerating. The midpoint was bumped slightly to $7.09 from the prior $6.90. This upward revision is mathematically supported by the massive reduction in the share count from the Q2 buybacks.
Key Questions
Intelligent Automation Reversal
Despite framing AI and Blue Prism as structural tailwinds and launching WorkHQ, the segment's organic growth flipped to -1.0%. Is this a timing issue with large license renewals, or are you seeing competitive pricing pressure in the RPA space?
Sustainability of Wealth and Intralinks
Wealth and Intralinks grew 9.8% and 7.4% organically, a sharp reversal from Q1. How much of this was pent-up demand or slipped deals finally closing versus a sustainable new run-rate?
Capital Allocation Framework
You deployed $435M into buybacks this quarter, keeping leverage flat at 2.75x. Should investors expect this elevated pace of buybacks to continue through H2, or are you building dry powder for near-term M&A?